Moses Makunje
Director of Finance/CFO en NUVATION BIO INC. .
Fortuna: 38 628 $ al 31/03/2024
Perfil
Moses Makunje is currently the Chief Financial & Accounting Officer at Nuvation Bio, Inc. He previously worked as the Corporate Controller at Maze Therapeutics, Inc. from 2019 to 2020.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 29/02/2024 | 10 612 ( 0.00% ) | 38 628 $ | 31/03/2024 |
Cargos activos de Moses Makunje
| Empresas | Cargo | Inicio |
|---|---|---|
| NUVATION BIO INC. | Director of Finance/CFO | 27/11/2023 |
Antiguos cargos conocidos de Moses Makunje.
| Empresas | Cargo | Fin |
|---|---|---|
Maze Therapeutics, Inc.
 Maze Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Maze Therapeutics, Inc. is a is a biopharmaceutical company, which engages in the development of portfolio of therapeutic candidates for a number of genetically defined diseases. It focuses on translating genetic insights into new medicines by utilizing an approach that combines the analysis of large-scale human genetics data, cutting-edge functional genomics, and an array of drug discovery approaches. The company was founded by Mark Daly, Aaron D. Gitler, Stephen Elledge, Sekar Kathiresan, and Jonathan S. Weissman in 2018 and is headquartered in San Francisco, CA. | Comptroller/Controller/Auditor | 01/07/2020 |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| NUVATION BIO INC. | Health Technology |
| Empresas privadas | 1 |
|---|---|
Maze Therapeutics, Inc.
Maze Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Maze Therapeutics, Inc. is a is a biopharmaceutical company, which engages in the development of portfolio of therapeutic candidates for a number of genetically defined diseases. It focuses on translating genetic insights into new medicines by utilizing an approach that combines the analysis of large-scale human genetics data, cutting-edge functional genomics, and an array of drug discovery approaches. The company was founded by Mark Daly, Aaron D. Gitler, Stephen Elledge, Sekar Kathiresan, and Jonathan S. Weissman in 2018 and is headquartered in San Francisco, CA. | Commercial Services |
- Bolsa de valores
- Insiders
- Moses Makunje
